Previous Article | Next Article 
Journal of Virology, March 1999, p. 2385-2393, Vol. 73, No. 3
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
U1 Small Nuclear Ribonucleoprotein and Splicing
Inhibition by the Rous Sarcoma Virus Negative Regulator of
Splicing Element
Lisa M.
McNally and
Mark T.
McNally*
Department of Microbiology and Molecular
Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226
Received 10 September 1998/Accepted 12 November 1998
 |
ABSTRACT |
Retroviruses require both spliced and unspliced RNA for
replication. Accumulation of unspliced Rous sarcoma virus RNA is
facilitated in part by a negative cis element in the
gag region, termed the negative regulator of splicing
(NRS), which serves to repress splicing of viral RNA but can also block
splicing of heterologous introns. The NRS binds components of the
splicing machinery including SR proteins, U1 and U2, small nuclear
ribonucleoproteins (snRNPs) of the major splicing pathway, and U11
snRNP of the minor pathway, yet splicing does not normally occur from
the NRS. A mutation that abolishes U11 binding (RG11) also abrogates
NRS splicing inhibition, indicating that U11 is functionally important
for NRS activity and suggesting that the NRS is recognized as a
minor-class 5' splice site (5' ss). We show here, using specific NRS
mutations to disrupt U11 binding and coexpression of U11 snRNA genes
harboring compensatory mutations, that the NRS U11 site is functional
when paired with a minor-class 3' ss from the human P120 gene.
Surprisingly, the expectation that the same NRS mutants would be
defective for splicing inhibition proved false; splicing inhibition was
as good as, if not better than, that for the wild-type NRS. Comparison of these new mutations with RG11 indicated that the latter may disrupt
binding of a factor(s) other than U11. Our data suggest that this
factor is U1 snRNP and that a U1 binding site that overlaps the U11
site is also disrupted by RG11. Analysis of mutations which selectively
disrupted U1 or U11 binding indicated that splicing inhibition by the
NRS correlates most strongly with U1 snRNP. Additionally, we show that
U1 binding is facilitated by SR proteins that bind to the 5' half of
the NRS, confirming an earlier proposal that this region is involved in
recruiting snRNPs to the NRS. These data indicate a functional role for
U1 in NRS-mediated splicing inhibition.
 |
INTRODUCTION |
Most protein-encoding genes in
metazoans are interrupted by introns which must be accurately spliced
out of the pre-mRNA to generate mRNA. The excision process involves two
transesterification reactions and takes place in a large macromolecular
complex, called the spliceosome, that is composed of several small
nuclear ribonucleoprotein (snRNP) particles and a large number of
non-snRNP factors (28). While there is considerable
understanding of the splicing reaction itself, much less is known about
how splice sites are appropriately paired. The problem becomes more
complicated in the many instances of alternative splicing, where
different combinations of splice sites are utilized to ultimately
generate different proteins from a common pre-mRNA (38).
Many viruses that infect eukaryotic cells have evolved to exploit RNA
splicing as a means to expand the coding capacity of their typically
small genomes and as a mechanism of posttranscriptional gene
regulation. As an extreme example, human immunodeficiency virus (HIV)
utilizes numerous 5' and 3' splice sites (5' and 3' ss) in a temporal
manner to generate an estimated 40 different mRNAs in an infected cell
(32, 35).
In addition to alternative splicing observed in some viruses,
incomplete RNA splicing is a feature common to all retroviruses. The
primary transcript serves as an mRNA for the Gag-Pol proteins or as
genome for progeny virions, but a population must also be spliced to
subgenomic mRNAs, which in the simplest cases encode the Env protein
(6). In HIV, it appears that the 5' ss are efficiently
recognized and that regulation occurs at the 3' ss (31);
both positive and negative elements that contribute the HIV 3' ss
control have been described (1, 36, 39). In Rous sarcoma
virus (RSV), splicing control is achieved through the action of several
cis elements, two of which represent the env and
src 3' ss themselves, which are maintained in suboptimal
forms (18, 49). Another element that is located upstream of
the src 3' ss controls src splicing specifically
and also has a mild inhibitory effect on heterologous introns (2,
4, 25, 48). Elements required for cytoplasmic accumulation of
retroviral RNA, the Rev/Rev response element system in HIV
(10) and constitutive transport elements in simian and avian
retroviruses (5, 30, 37), might also influence the
unspliced/spliced RNA ratio by modulating the availability of the
unspliced RNA pool for splicing. Efficient replication of RSV requires
a precise balance between spliced and unspliced RNA since viruses that
display even modest increases in splicing efficiency exhibit
replication defects (17, 49).
Besides the elements that are coincident with or reside near splice
sites, RSV contains a novel negative element in the gag gene
that is remote from the splice sites yet acts in a global manner to
regulate splicing. Deletions in this element, termed the negative
regulator of splicing (NRS), result in a substantial increase in
splicing at both the env and src 3' ss (3,
40). The NRS can also block splicing of heterologous introns in
vivo and in vitro (14, 26), indicating that NRS inhibition
is not unique to the viral context but rather results from a general effect on splicing. The importance of accumulating large amounts of
unspliced viral RNA is underscored by the presence of multiple and
diverse control elements, all of which are required to achieve the
proper ratio of unspliced to spliced RNA.
While maintenance of suboptimal 3' ss and splice site-specific
inhibitory elements are common features of in retrovirus splicing control, the NRS element has been described only for avian
retroviruses. Efforts to understand how the NRS inhibits splicing have
suggested a major role for components of the splicing machinery itself. Mapping studies demonstrated that two subregions of a ~227-base RNA
fragment are required for splicing inhibition (26). The downstream region is necessary but not sufficient for splicing inhibition and harbors sequences with similarity to 5' and 3' ss. It
was shown that U1 and U2 snRNP particles, abundant splicing factors
that interact with 5' and 3' ss, respectively, bind the NRS in vitro
(14). The same study revealed binding of a third and
lower-abundance snRNP, U11, to the downstream region. The U11 snRNP
interaction appears important for function since NRS mutations that
abolish U11 binding also substantially reduce splicing inhibition
activity. Mutations that specifically abolish U1 and U2 binding have
yet to be identified, and the significance of their binding has been
ambiguous. The upstream region of the NRS contains a ~35-nucleotide
(nt) purine-rich region that is also necessary but not sufficient for
inhibition and to which the SR protein splicing factor SF2/ASF binds
(24). Members of the SR protein family of splicing factors
have several activities, including facilitating the entry of snRNP
particles into the assembling spliceosome and mediating the function of
RNA splicing enhancers (13, 22, 44). These two aspects of SR
protein function are likely to be important for NRS action because the
purine-rich NRS 5' region (NRS5') has enhancer activity and
heterologous enhancers can substitute for NRS5' and support splicing
inhibition (23).
U11 snRNP was recently shown to be the U1 counterpart for 5' ss
recognition in a spliceosome that excises a minor class of introns that
contain noncanonical splice sites (15, 20, 42, 43). These
introns are often referred to as minor-class introns. Rather than
having /GT (the slash denotes the splice site) and AG/ terminal
dinucleotides that are characteristic of a loosely conserved consensus
associated with most nuclear pre-mRNA introns (5' ss AG/GTRAGT), the
minor introns were originally described as being bounded by /AT and AC/
but also adhering to a much stricter 5' consensus sequence,
/ATATCCTT. The /AT-AC/ nature of the junctions also led to the term
"attack" introns (29). More recently, minor-class introns containing /GT and AG/ termini have been identified, but the
remainder of the sequences clearly resemble the minor-class consensus
(11). Since the terminal dinucleotides no longer specify which splicing pathway a particular intron will use, the major and
minor introns are also called U2-dependent and U12-dependent introns,
respectively (11). Like the major spliceosome, a minor spliceosome assembles in a stepwise fashion through the sequential addition of other unique snRNPs (U12, U4atac, and U6atac) that serve
functions analogous to the major pathway counterparts (U2, U4, and U6);
U5 snRNP is present in both spliceosomes (16, 20, 41, 42).
Significantly, the short sequence in the NRS 3' region that is required
for U11 binding (/GTATCCTT) matches the highly conserved minor-class 5'
ss consensus sequence.
In vitro, the NRS assembles into an RNP complex that is dependent on SR
proteins and U1 and U11 snRNPs (but not U2), and whose characteristics
most closely resemble complexes that assemble on a U1-dependent 5' ss
(7, 9). Despite binding SR proteins and U1/U2 snRNPs from
the major splicing pathway, our efforts to force splicing from the NRS
have been unsuccessful, even when it is paired with 5' or 3' ss that
are normally used efficiently. This observation, the general lack of
data supporting a functional role for U1 binding, and the apparent
importance of U11 snRNP for inhibition have led us to propose that the
NRS is primarily recognized as a minor-class 5' ss that elicits
splicing inhibition when placed within major-class introns
(23).
In this work, we tested the notion that the NRS might serve as a
minor-class 5' ss in the appropriate context and found (i) that
splicing did occur to an authentic minor-class (U12-dependent) 3' ss
from the human P120 gene in transfected cells and (ii) that U11 snRNP
was required for splicing. Surprisingly, an NRS mutation that abolished
U11 binding in vitro and minor pathway splicing in vivo still blocked
splicing of a U2-dependent heterologous intron, suggesting that a
factor other than U11 was responsible for splicing inhibition. Data
presented here indicate that binding of U1 snRNP to a sequence that
overlaps the U11 site most strongly correlates with splicing inhibition
by the NRS. The U1 site must be suboptimal, since splicing was
activated when the site was mutated to match the U1 consensus. We
further show that the upstream purine-rich element, through SR
proteins, is required for efficient U1 snRNP binding in vitro. Thus,
while U1 was known to bind the NRS, our data now suggest that binding
is an important event in splicing inhibition.
 |
MATERIALS AND METHODS |
Plasmid constructs.
RSV fragments were from the Prague C
strain (27); sequence coordinates are as specified by
Schwartz et al. (34). Plasmids harboring human P120 genomic
fragments encompassing wild-type exons 5 to 8, or containing the CT67GA
and TT78AA mutations at the minor-class 5' ss, and U11 snRNA gene
expression plasmids were generously provided by R. Padgett (Cleveland
Clinic) (16, 20). pP120 contains P120 exon 6, intron F (a
minor-class intron), and most of exon 7 inserted into the
HindIII-BamHI sites of pRSV2 (26).
The P120 fragment, generated by PCR (all primer sequences available
upon request), contained nt 1 of exon 6 through nt 180 of exon 7 and
had HindIII and BglII sites appended to the
5' and 3' ends, respectively. The chimera pNRS-P120 was created by
replacing the HindIII-Bsu36I fragment of
pP120 (exon 6 through position 61 of the 99-nt intron) with an NRS PCR
fragment harboring nt 714 to 979 (to which HindIII and
Bsu36I restriction sites were appended to the 5' and 3'
ends, respectively). Mutations depicted in Fig.
1A were introduced into pNRS-P120 either
by replacement of P120 sequences with PCR fragments derived from mutant
NRS DNA or by site-directed mutagenesis of NRS sequences in pNRS-P120 by the U.S.E. (unique site elimination) method (Pharmacia Biotech).

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 1.
Splicing from the NRS to a U12-dependent 3' ss. (A)
Diagram of P120 and NRS-P120 chimeric constructs. A two-exon construct
containing the human P120 gene exons 6 and 7 (open boxes) and
intervening minor class intron (line) were expressed from the RSV
promoter (not shown). The minor-class 5' and 3' ss sequences are shown,
and the nucleotide positions at the 5' ss are numbered. The NRS
portions of the chimeric constructs are in gray, with the thick and
thin regions representing sequences upstream and downstream,
respectively, of the U11 site. The sequences of the NRS and mutant U11
sites are shown, with the changes in lowercase and underlined. The
diagram is not to scale. (B) RT-PCR of RNA from transfected 293 cells.
Below the gel is a schematic of the RT and PCR primers. Total RNA (2 µg) was reverse transcribed with a primer to common vector sequences,
cDNA was subjected to PCR with an upstream vector primer and a
downstream P120 exon 7 primer (see Materials and Methods), and the PCR
products were resolved in an agarose gel and stained with ethidium
bromide. The image was captured electronically, and the pixels were
inverted. The names above the lanes refer to the constructs in panel A. Mock, transfection with an empty expression vector; M, 100-bp markers.
Bands corresponding to unspliced (Un) and spliced (Sp) are indicated on
the right.
|
|
To test for splicing inhibition activity, NRS fragments were inserted
into the
SacII intron position of the
myc intron
of
pRSVNeo-int (
21), using the
KpnI-
XbaI fragment shuttling approach
described
previously (
23). All fragments consisted of nt 701
to 1011 and had
KpnI and
XbaI sites appended to the 5'
and 3'
ends by PCR. Fragments to be used to generate RNA for affinity
selections were also inserted into pGEM-3Z. NRS mutations were
created
either with a U.S.E. kit (Pharmacia Biotech) or by recombinant
PCR
(
33). The mutations are indicated in the figures. All
sequences
were verified by DNA
sequencing.
Transfection of 293 cells and analysis of RNA.
293 cells
were grown in minimal essential medium supplemented with 10% fetal
calf serum and penicillin-streptomycin. Cells grown to about 40 to 60%
confluence in 6-cm-diameter dishes were transfected with 2 to 3 µg of
DNA by the calcium phosphate method (Pharmacia Biotech), and total RNA
harvested 40 h later was isolated with Qiagen RNAeasy columns
according to the manufacturer's instructions. For reverse
transcription (RT)-PCR, 1 µg of total RNA was reverse transcribed
with an antisense primer directed to pRSV2 vector sequences downstream
of the transcription unit (GCAGACACTCTATGCCTGTGTGG) and
common to all RNAs in 20 µl, using 200 U of reverse transcriptase (GibcoBRL) and the manufacturer's recommended reaction conditions. Two
microliters of the RT reaction was subjected to 28 cycles of PCR using
a 5' vector primer directed upstream of the transcription unit
(CACCACATTGGTGTGC) and a 3' primer to sequences in P120 exon 6. Thus, the same primer pair was used for all constructs. RNase protection assays were as described elsewhere (23), using 5 µg of RNA. A plasmid for generating the 3' ss probe was made by inserting a blunt-ended AflII-PstI fragment from
pRSVNeo-int that spans the 3' ss into the pGEM-3Z SmaI site
such that T7 RNA polymerase and HindIII-cut DNA
generated an antisense probe. Quantitation was done with a Molecular
Dynamics Storm 860 PhosphorImager.
Affinity selection.
Affinity selection was performed
essentially as described previously (9). Briefly, RNA
transcribed in vitro in the presence of biotin-11-UTP (20% of total
UTP) from pGEM constructs linearized with XbaI was incubated
under splicing conditions with ATP in HeLa cell nuclear extract
(12) for 30 min at 30°C. Streptavidin-agarose beads were
added and mixed at 300 mM KCl for 1 h at 4°C and then washed
extensively at 300 mM KCl. Bound nucleic acids were released by
proteinase K digestion, phenol extracted, precipitated with ethanol,
and subjected to electrophoresis in a 8 M urea-8% polyacrylamide gel.
RNA was electroblotted to a ZetaProbe membrane (Bio-Rad) and hybridized
with riboprobes to U1 and U11 snRNA; the membrane was then subjected to autoradiography.
 |
RESULTS |
Splicing from the NRS to a U12-dependent 3' ss requires U11
snRNP.
Given that the NRS interacts with a number of splicing
factors, one might expect the NRS to be productively used as a splice site under certain conditions, yet our efforts to detect splicing to or
from the NRS in a variety of contexts have been unsuccessful. The
description of U11 snRNP as the component of the minor splicing pathway
that recognizes the 5' ss of U12-dependent introns (20, 46)
prompted us to investigate whether our failures to detect NRS splicing
stemmed from its inappropriate pairing with major-class splice sites.
Might the NRS function in splicing if paired with a minor-class,
U12-dependent 3' ss? To examine this possibility, we made a number of
chimeras utilizing the RSV promoter by fusing the NRS to a human P120
gene fragment encompassing part of intron F and exon 7 that contains a
U12-dependent 3' ss (Fig. 1A). The parental vector contained most of
the P120 exon 6, the entire intron F, and most of exon 7. A similar
construct containing P120 exons 5 through 8 is known to splice
accurately in vivo (16), and exon 6 is spliced to exon 7 accurately in vitro (11, 42). For the NRS-P120 chimeras, the
P120 exon 6 and 61 nt of the 99-nt intron were replaced with NRS
sequences. The NRS fragment contained nt 719 to 979 and so contained 61 nt downstream of the putative U11 5' ss such that if the site were
active, the intron would be the natural size of P120 intron F, 99 nt.
As controls, additional constructs contained the RG11 NRS mutation that
abolishes U11 binding and splicing inhibition (14) and would
be expected to abrogate minor-class splicing; a G-to-A change at the
first nucleotide of the U11 consensus to give an AT dinucleotide (AT),
which should not affect U11 binding or function (11); a
GT-to-TC change at positions 1 and 2 (TC) which would abolish splicing
but would not be predicted to significantly affect U11 binding; and
CT67GA and TT78AA mutations that are known to abolish P120 splicing
(20). The constructs were transfected into 293 cells, and
the extent of splicing was assessed by subjecting the harvested RNA to
RT-PCR with an RT primer to downstream vector sequences, and PCR
primers to upstream vector sequences and downstream P120 exon 7, sequences common to all constructs. Control reactions which lacked RT
showed that the PCR signals were due to expression of transfected
plasmids rather than endogenous P120 mRNA or DNA (data not shown).
As expected for the P120 RNA, RT-PCR products of the size expected for
unspliced and spliced RNA were observed, with the spliced
product
predominating (Fig.
1B, lane 1). When P120 exon 6 and
the upstream
two-thirds of the intron were replaced with the NRS,
a band whose size
was consistent with utilization of the NRS U11
5' and P120 3' splice
sites was observed (lane 2), and the splicing
efficiency of the
NRS-P120 chimera was similar to that for the
P120 construct. Thus,
pairing the NRS with a minor-class 3' ss
activated splicing from the
NRS for the first time in our hands.
Southern blotting with intron and
exon probes confirmed the conclusion
that the bands were derived from
unspliced and spliced RNA (data
not shown). Significantly, the putative
spliced product was not
observed with the RG11 mutant that fails to
bind U11 snRNP in
vitro and that would be expected to abolish minor
pathway splicing
(lane 3). Further support for the idea that splicing
occurred
from the NRS U11 site stemmed from the result with the A-to-T
mutation. If the observed splice had occurred by aberrant U1
recognition
of the GT dinucleotide associated with the NRS U11 site,
the AT
mutation might be expected to abolish splicing, whereas an A at
the +1 position should have little effect on minor-class splicing.
Consistent with the latter possibility, splicing was still observed
with the AT mutation (lane 4). In addition, three mutations expected
to
inactivate the NRS U11 site, two of which should be highly
specific to
U11 (CT67GA and TT78GA) (
20), completely abolished
the
spliced band. These data are most compatible with the NRS
splice
occurring via the minor pathway at the predicted U11
site.
Still, the presence of several U1-like 5' ss sequences and the
previously observed U1 snRNP binding to the NRS (
14),
coupled
with the presence of a /GT rather than an /AT in the minor 5'
consensus, left open the possibility that the splicing observed
with
NRS-P120 chimera resulted from the major pathway via U1 snRNP,
perhaps
to one of several AG/ dinucleotides surrounding the P120
U12-dependent
3' ss. To address this, a number of independent
cDNAs representing the
NRS-P120 spliced RNA were cloned and sequenced
to determine the splice
junctions. Sequencing of the control P120
mRNA showed accurate splicing
(/AT to AC/), and the predicted
NRS /GT 5' ss was always used in
NRS-P120 mRNA, but in no instance
was the authentic P120 AC/ 3' ss used
(data not shown; see Discussion).
Rather, in the majority of cases the
splice junction was shifted
two nucleotides downstream to an AT/
dinucleotide (22 of 27 sequences),
with five cDNAs showing an AG/
junction at +8. Interestingly,
this apparent anomaly might have been
expected since this is exactly
what is observed when the 5' ss is
changed from AT to GT in P120
splicing; however, the GT-to-AT and
GT-to-AG splicing was still
by the minor pathway (
11). As
expected, sequencing of the NRS
AT-P120 cDNA showed accurate minor
class splicing (AT to AC [data
not shown]). Thus, the sequencing data
were highly suggestive
but not conclusive enough to unambiguously
assign the splicing
observed with NRS-P120 to the minor
pathway.
Recently, a genetic approach was taken to demonstrate that U11
functionally interacts with the P120 5' ss (
20).
Specifically,
the splicing defect of the CT67GA mutant 5' ss was
suppressed
by coexpression of a U11 snRNA gene harboring a compensatory
mutation
(AG56TC) predicted to reestablish base pairing with the
substrate.
The base pairing potential of U11 snRNA with the NRS is
shown
in Fig.
2A. To definitively show
that the minor pathway was utilized
for NRS-P120 splicing, we similarly
coexpressed mutant U11 genes
with the CT67AG NRS-P120 chimera. As shown
in Fig.
2B, a modest
level of splicing was restored to the CT67GA
mutant chimera when
the U11 AG56TC gene (lane 5) was coexpressed.
However, no splicing
was observed when an inappropriate U11 allele was
used (lane 4),
indicating specific suppression of the NRS mutation by
the altered
U11 snRNA. These data are strong evidence that the splicing
from
the NRS in the chimera was by the minor pathway.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
Allele-specific suppression of the CT67GA mutant
splicing defect by expression of compensatory U11 snRNA. (A) Potential
base pairing interaction between the NRS and U11 snRNA. The NRS CT67GA
mutation and the U11 snRNA compensatory mutations (AG56CT and AA45TT)
at the 5' end of U11 are shown. (B) RT-PCR of RNA from transfected 293 cells was performed as described in the legend to Fig. 1. Lanes 3 to 5 are reactions from the cells transfected with the NRS CT67GA mutant.
Indicated below is cotransfection with an empty vector ( ), or the
AA45TT (45) or AG56CT (56) U11 snRNA expression plasmid. The arrowhead
indicates the spliced band restored by the compensatory AG56CT U11
construct.
|
|
NRS U11 snRNP binding mutant (CT67GA) still blocks splicing.
Having shown genetically that the U11 5' ss associated with the NRS can
function the correct context, we set out to demonstrate that splicing
inhibition was also mediated by U11 snRNP. NRS inhibition activity was
assessed by monitoring the splicing efficiency in transfected 293 cells
of a heterologous intron into which the NRS is inserted, as shown in
Fig. 3A (26). The distance of
the insertion site from the 5' ss is similar to the natural location of
the NRS in RSV. Our expectation was that the NRS CT67GA mutant would no
longer inhibit splicing and that splicing inhibition would be restored
by coexpression of the compensatory U11 snRNA. As expected, the NRS
elicited splicing inhibition in an orientation-specific manner (Fig. 3,
lanes 3 and 4), and the RG11 mutation eliminated splicing inhibition
(lane 5), consistent with an elimination of U11 binding. Surprisingly,
the CT67GA mutation had no effect on splicing inhibition and sometimes
resulted in slightly more unspliced RNA. A similar result was obtained
with the TT78AA mutant (data not shown). Thus, the same mutations that
eliminated minor-class splicing in the NRS-P120 chimera had no effect
on splicing inhibition.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 3.
The CT67GA NRS mutation does not impair NRS splicing
inhibition. (A) Diagram of the pRSVNeo-int construct and RNase
protection probes used to measure NRS activity. Open boxes indicate Neo
sequences, black boxes represent the small portions of myc
exons, and the line denotes the myc intron. Above is a
schematic of the RNase protection probes and protected fragments. The
shaded box represents NRS fragments that were inserted into the
SacII site (S) of the myc intron of pRSVNeo-int.
The sequence surrounding the U11 site of the mutant and wild-type NRS
fragments is shown. The dots indicate unchanged bases; changes are in
lowercase. The U11 site is overlined. (B and C) RNase protection assays
on RNA from transfected 293 cells. Total RNA from 293 cells transfected
with the indicated constructs was used for RNase protection with 5' ss
(B) and 3' ss (C) probes (see Materials and Methods), and protected
fragments were run on a 4% (B) or 6% (C) denaturing polyacrylamide
gels and visualized by autoradiography. M, markers; P, unprocessed
probe; myc, pRSVNeo-int with no insert; + and , sense and antisense
orientations of the NRS; RG11 and CT67GA (67) NRS mutants; mock, RNA
from mock-transfected cells; Un and Sp, positions of bands representing
unspliced and spliced RNA. Below the lanes is the quantitated percent
unspliced RNA as determined by PhosphorImager analysis; the data are
representative of at least three separate experiments.
|
|
It was possible that the lack of inhibition observed with NRS CT67GA
was an artifact of using a probe to the 5' ss to assay
splicing of the
test intron. For example, the specific elimination
of U11 binding may
have activated major-class splicing from the
NRS to the normal test
intron 3' ss such that the probe would
then be hybridizing to upstream
exon sequences; the full-length
protected probe would no longer be
diagnostic for splicing. This
was addressed by subjecting the same RNA
to RNase protection with
a probe to the 3' ss, the results from which
should differ from
the 5' ss probe data if cryptic splicing is
activated within the
NRS. The results with the 3' ss probe mirrored
those with the
5' ss probe (Fig.
3C), favoring the conclusion that the
CT67GA
mutation failed to abolish splicing inhibition. One
interpretation
is that the CT67GA mutation may have had no effect on
U11 binding
and splicing inhibition but selectively abolished the
splicing
potential of the chimeras used for Fig.
1 and
2.
Alternatively,
a factor other than or in addition to U11 snRNP may be
responsible
for splicing inhibition by the
NRS.
snRNP binding to the NRS.
In addition to having four changes
in the U11 binding sequence rather than the two changes present in
CT67GA, the original U11 binding mutation, RG11, contains three other
changes immediately upstream of the U11 site (Fig. 1A) which could be
the source of the different inhibition activities observed above for
the two mutations. Interestingly, this sequence is similar to a U1-type 5' ss (TG/GTTTGT versus the AG/GTRAGT consensus), and the NRS is known
to bind U1 (14) although the binding site(s) has not been
identified. Thus, the RG11 mutation might simultaneously affect U11 and
U1 binding sites. The base pairing potential of U1 and U11 is shown in
Fig. 4A. This possibility was directly addressed by examining the effect of RG11 on U11 and U1 snRNP binding.
Biotinylated RNA transcripts of the NRS and a number of mutants (Fig.
4B) were incubated in nuclear extract and affinity selected with
streptavidin agarose, and the associated snRNPs were identified by
Northern blotting of extracted RNAs. A representative result is shown
in Fig. 4C, and the percentage of U1 and U11 binding of the mutants
relative to the wild type is presented in Fig. 4B. We recently reported
that U11 snRNP is poorly selected by NRS nt 701 to 932 (9),
but as shown in Fig. 4C, U11 binding to NRS nt 701 to 1011 is much more
efficient (lane 3 and data not shown). When RG11 was used, the U11
signal was virtually eliminated, as expected, but the U1 signal was
also decreased by about 90% (lane 4). In contrast, the U11-specific
mutations CT67GA and TT78AA also eliminated U11 binding but resulted in
more efficient U1 binding (lanes 5 and 6). These results suggest that a
U1 binding site is very close to the U11 site. Also, the increased U1
binding to the U11 mutants suggests that the two snRNPs compete for
binding to the same region and perhaps to overlapping sequences.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 4.
A U1 snRNP binding site overlaps the U11 site. (A)
Diagram of potential base pairing interactions (vertical lines) of U1
and U11 snRNA with the NRS. The NRS U1 site is underlined; the U11 site
is overlined; slashes indicate where splicing would be predicted to
occur if the sites were functional. (B) Sequences of NRS and mutants
used for affinity selection. To the right, bands in panel C were
quantitated with a PhosphorImager, and the intensity of each of the U1
and U11 signals generated by the mutants was compared to that for
wild-type (WT) NRS RNA, which was set to 100%. (C) Affinity selection.
Equal moles of the indicated biotinylated RNAs were incubated in
nuclear extract and affinity selected with streptavidin-agarose beads,
and snRNA components of snRNPs associated with the NRS were extracted
with phenol-chloroform (see Materials and Methods). The extracted RNA
was resolved in a denaturing polyacrylamide gel, electroblotted to a
nylon membrane, and hybridized with U1 and U11 antisense riboprobes.
Background binding to the beads was determined with nonbiotinylated RNA
( ). NE, U1 and U11 snRNA markers extracted from 3 µl of nuclear
extract. The positions of U1 and U11 are indicated on the right.
|
|
One prediction of the overlapping binding site model is that U11
binding would be unaffected by the AT mutation but that since
the
mutated G is at the important +5 position for U1 (
28), U1
binding would be affected. As predicted, U1 binding to AT was
greatly
reduced whereas U11 binding was largely unaffected (Fig.
4C, lane 7).
Additionally, the TC and GC mutations had severe
and mild effects on U1
binding, as expected (lanes 8 and 9). Surprisingly,
these two mutations
also eliminated U11 binding, indicating that
changing the second
position in the U11 consensus, which is not
predicted to contribute to
base pairing interactions with U11,
nonetheless has a significant
impact on U11 binding in this assay.
The mU1 mutant, which should
specifically reduce U1 binding, nearly
eliminated U1 binding and
resulted in a small but reproducible
increase in U11 binding (lane 10).
Thus, mutations designed to
impact binding of both snRNPs, and likewise
mutations targeted
to one or the other snRNP, had the predicted
effects. These data
support the view that U1 and U11 binding sites
overlap, sharing
a central GT. Therefore, it is possible that the
effect of previous
mutations on NRS function might have been through
disruption of
U1 binding rather than U11, or
both.
U1 snRNP binding correlates with splicing inhibition.
Having
shown that the CT67GA mutation retains inhibitory activity (Fig. 3) and
that the RG11 mutation affects both U11 and U1 snRNP binding (Fig. 4),
we used selected mutants to determine the effect of mutating the
putative U1 site while preserving U11 binding on NRS splicing
inhibition (Fig. 5A). The wild-type NRS and RG11 served as positive and negative controls. As shown in Fig. 5B,
compared to the wild type (lane 3), unspliced RNA accumulation was
decreased substantially when the RG11, AT, TC, and mU1 mutants were
inserted into the test intron at the SacII site (lanes 5 to
7 and 10). This finding is consistent with the loss of U1 binding for
each (Fig. 4C) but would not expected for AT and mU1 if U11 contributes
to splicing inhibition. The level of unspliced RNA with the
U11-specific CT67GA and TT78AA mutants was similar to or slightly
higher than the wild-type level (lanes 8 and 9), again suggesting that
U11 binding in not required for splicing inhibition. These results
establish a correlation between splicing inhibition and U1 binding and
indicate that U11 binding is of less importance.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 5.
Selective mutation of the U1 site severely reduces NRS
splicing inhibition. (A) The sequence of the U1 and U11 sites of the
NRS is shown at the top. Slashes indicate where splicing would occur if
the sites were used. Below are sequences of the mutants, with mutations
in lowercase and unchanged bases indicated as dots. The U1 site is
underlined; the U11 site is overlined. The fragments were inserted into
the SacII intron site of pRSVNeo-int. (B) RNase protection
assay on RNA from transfected 293 cells. Total RNA from 293 cells
transfected with the indicated constructs was used for RNase protection
with the 5' ss probe as for Fig. 3B. Un and Sp, positions of bands
representing unspliced and spliced RNA. Below the lanes is the percent
unspliced RNA as determined by PhosphorImager analysis; the data are
representative of at least three separate experiments.
|
|
A consensus U1 site activates splicing from the NRS.
The NRS
U1 site deviates from the consensus U1 5' ss at positions
2, +3, and
+4. Since the above results indicated that U1 binding is important for
splicing inhibition, the constructs in Fig.
6A were used to determine if altering the
NRS U1 site to match the consensus would result in more potent splicing
inhibition. Both a mutant containing a consensus U1 site and the normal
overlapping U11 site (cU1) and a construct harboring the U11 CT67GA
mutation and the improved U1 site (cU1-67) appeared to inhibit splicing more efficiently than wild type when assayed with the 5' ss probe (Fig.
6B; compare lanes 5 and 6 to lane 3). The U11 site was also changed to
the U1 consensus in the cU1 background, generating two overlapping U1
sites. Again, a higher than normal level of inhibition was observed
(data not shown). The U1 and U11 sites were also separated by 22 nt to
relieve competition, but this construct (Spc) produced normal levels of
unspliced RNA. Thus, it appeared that a stronger U1 site resulted in
increased splicing inhibition efficiency. However, as in Fig. 3, the
result with the 5' ss probe would be artifactual if the consensus U1
sites were actually used for splicing. When the same RNAs were used in
RNase protection assays with the 3' ss probe to control for this
possibility (Fig. 6C), roughly 90% of the RNA appeared to be spliced
when a consensus U1 site was present (lanes 6 and 7). These data are
consistent with splicing occurring from the NRS in the mutants
containing a consensus U1 site. This possibility was confirmed by
sequencing RT-PCR products generated from the same RNA. The size of the
products was consistent with splicing from the NRS to the
myc 3' ss (data not shown) and the sequence indicated
splicing from the consensus U1 sites to the normal myc 3' ss
of the test intron (Fig. 6D). We conclude that the NRS U1 site must be
suboptimal to inhibit splicing; consensus sites are productively used.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 6.
Productive splicing from a consensus NRS U1 site. (A)
Schematic of pRSVNeo-int, 5' and 3' ss probes, and NRS insertion site.
Relevant sequences of the NRS (U1 site underlined, U11 site overlined)
and mutants inserted into the SacII site (S) of the
pRSVNeo-int test intron are shown. Dots indicate unchanged bases;
changes are in lowercase; slashes (/) indicate where splicing would be
predicted to occur if the U1 or U11 sites were functional. For the
spacer (Spc) construct, the U1 and U11 sites were separated by 22 nt.
(B and C) Results of RNase protection assays on RNA from transfected
293 cells obtained with the 5' ss and 3' ss probes, respectively (note
the difference in lane order). Below the lanes is the quantitated
percent unspliced RNA as determined by PhosphorImager analysis; the
data are representative of at least three separate experiments. Un and
Sp, positions of bands representing unspliced and spliced RNA. (D)
Sequence of cDNA from spliced RNA. The cut RNA samples used for panels
B and C were subjected to RT-PCR, and the PCR products corresponding to
spliced RNA were sequenced. The relevant sequence of the NRS and
myc 3' ss is shown. Intron sequences are represented by
dots, the terminal myc nucleotides are in lowercase, and the
myc exon sequence is in uppercase.
|
|
The NRS purine region and SR proteins promote snRNP binding to the
NRS.
The purine-rich NRS5' binds SR proteins, possesses RNA
splicing enhancer activity, and is required for splicing inhibition. We
previously proposed that the purine region might function by promoting
snRNP binding to the NRS (23). However, in nuclear extract
only a small positive effect of NRS5' on U11 binding has been observed.
The above data indicated a primary role for U1 in splicing inhibition
and led us to examine the effect of the purine region on U1 binding,
using the affinity selection assay and the RNAs shown in Fig.
7A. As shown above, U1 and U11 were efficiently selected by the NRS (Fig. 7B, lane 4), whereas the mU1
mutation substantially reduced U1 binding while modestly increasing U11
binding (lane 6). The NRS lacking the purine region (
Pu) again
selected U11 with only slightly reduced efficiency, but U1 binding was
strongly affected (lane 5). These results suggest that U1 binding is
more strongly influenced by the purine region, and by extension SR
protein binding, than U11.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 7.
The NRS purine-rich region and SR proteins promote U1
snRNP binding to the NRS. (A) Diagram of the constructs used in
biotin-streptavidin affinity selection experiments. The larger and
smaller shaded regions indicate the NRS purine-rich region and snRNP
binding sites, respectively. (B) Affinity selection experiment. The
indicated biotinylated RNAs ( , nonbiotinylated NRS RNA) were
incubated in nuclear extract (NE; lanes 3 to 6), S100 (lanes 7 to 10),
or S100 supplemented with SR proteins (lanes 11 to 14), and the
complexes assembled on the RNA were affinity selected with
streptavidin-agarose. Bound nucleic acids were released by treatment
with proteinase K and phenol extracted, and RNA was electroblotted to a
nylon membrane and hybridized with U1 and U11 antisense riboprobes.
snRNA markers were extracted directly from nuclear extract or S100
(lanes 1 and 2). The positions of U1 and U11 are indicated to the
right.
|
|
We directly investigated the role of SR proteins in U1 and U11 binding
with an S100 extract that lacks SR proteins (
47).
Binding of
both snRNPs was strongly reduced in S100, regardless
of the substrate
used (Fig.
7B, lanes 8 to 10), which suggests
but does not prove that
SR proteins promote binding of U1 and
U11. When 1 µg of total SR
proteins purified from HeLa cells was
added to S100, binding of U1 was
rescued, but only in the presence
of the purine region and an intact U1
site (lanes 12 to 14). In
contrast, U11 binding was not restored in
S100, even with the
addition of up to 8 µg of SR proteins (data not
shown). It appears
that in addition to SR proteins, U11 binding
requires another
factor(s) that is not present in S100. Given that U11
binding
is less dependent on the purine region and that NRS activity in
vivo requires the purines, these results are most consistent with
a
primary role for U1 in splicing
inhibition.
 |
DISCUSSION |
Three snRNPs have been shown to interact with the NRS: U1 and U2
snRNPs of the major splicing pathway, and U11 snRNP of the minor
pathway. Deciphering which snRNPs are required for splicing inhibition
is important for understanding the mechanism by which the NRS
ultimately blocks splicing. Several observations have suggested a
primary role for U11 snRNP in NRS-mediated splicing inhibition. First,
U11 binding to the NRS is dependent on a critical sequence that matches
the minor class 5' ss consensus to which U11 is known to bind, and
mutation of this sequence abolished splicing inhibition of a
heterologous intron in vivo (14). Further, assembly of an
RNP complex on the NRS in vitro, NRS-C, is partially dependent on an
intact U11 site (7). Less certain were the roles for U1
and/or U2 snRNP, since their binding sites within the NRS had not been
identified and thus mutational studies had not been possible. U2 snRNP
is not required for NRS-C assembly in vitro (9), which can
be taken as evidence against a role for U2 in NRS activity. In
contrast, disruption or sequestration of U1 snRNP results in a large
decrease in NRS-C assembly (9). This result suggested a role
for U1 in NRS activity; however, without functional data, it was
possible that in vitro binding to the NRS reflected the high abundance
of U1 in nuclear extract. Surprisingly, the results reported here
provide strong evidence that a U1-type 5' ss overlaps the U11 site and
that U1 snRNP is, in fact, more important than U11 for splicing inhibition.
We speculated that our inability to force splicing from the NRS in
numerous contexts, despite its binding of splicing factors, stemmed
from the fact that it was always paired with major-class splice sites
which are thought to be incompatible with minor-class splicing
(19). Our results indicate that minor-class splicing can
occur efficiently from the NRS via U11 snRNP provided that a
U12-dependent 3' ss is supplied. Sequencing of chimeric cDNAs showed
that the /GT of the NRS U11 site was used but the natural P120 AC/ 3'
ss was not. Rather, a cryptic TG/ 2 nt downstream from the 3' ss was
preferentially used along with a nearby AG/ dinucleotide that is
characteristic of the major pathway. Dietrich et al. (11)
recently showed that mutation of the P120 gene U11 5' ss to GT, which
matches the NRS sequence, results in cryptic splicing to the very same
3' TG/ and AG/ dinucleotides and that splicing was by the minor
pathway. This work, our demonstration that NRS CT67GA-P120 splicing
could be restored in an allele-specific manner by expression of a
compensatory U11 snRNA, and accurate minor-class splicing from the
AT-P120 construct provide strong evidence that the NRS splice was by
the minor pathway. Interestingly, Weldon and Wills (45)
detected a splice from the /GT of the NRS U11 site to cytochrome
c sequences in an expression vector where the yeast
cytochrome c gene replaced PR in the RSV gag
gene. The 3' ss junction was an AG/ dinucleotide characteristic of a major class splice, but 8 nt upstream is a close match to the U12-dependent branch point sequence, suggesting that this splice was
also by the minor pathway and that the cyt gene sequences fortuitously provided a U12 site. We generalize these observations and
suggest that splicing from the NRS does not normally occur unless a
U12-dependent 3' ss is provided. We are unaware of any instance where a
major class splice has occurred from NRS, despite the many
configurations that have provided a U2-dependent 3' ss. Until this
study, these results were consistent with previous models of a role for
U11 snRNP in NRS-mediated splicing inhibition.
Based on the results with the NRS-P120 chimera, we fully expected the
CT67GA mutation to abolish splicing inhibition, just as it had
abolished splicing of the chimera. Surprisingly, CT67GA had no effect
on splicing inhibition. The demonstration that the mutation rendered
U11 binding almost undetectable indicates that U11 is not required for,
and perhaps is not involved in, NRS-mediated splicing inhibition. This
suggested that binding of a factor in addition to U11 is disrupted by
the original RG11 mutation, and that factor appears to be U1 snRNP.
Four observations suggest a major role for U1 snRNP binding in splicing
inhibition by the NRS. First, the mutations that selectively disrupted
U1 severely reduced splicing inhibition and slightly increased U11
binding. This finding is in conflict with a predominant role for U11.
Second, mutations that disrupted U11 binding resulted in an increase in U1 binding, and these mutants often showed enhanced splicing
inhibition. Third, we previously showed that NRS5' binds SR proteins
(24) and harbors splicing enhancer activity (23)
and proposed that this region is responsible for recruiting snRNPs to
the NRS. Our findings here that the NRS purine-rich region and SR
proteins are required for efficient U1 binding, but less so for U11, is consistent with a principal role for U1 snRNP in inhibition. Fourth, incapacitation of U1 has a dramatic affect on assembly of the NRS
complex in vitro (9), and selective mutation of the U1 site,
but not U11, abolished an in vitro interaction with a U2-dependent 3'
ss (see below) (8).
While our data suggest that U1 is of primary importance for the NRS, it
is still possible that U11 snRNP can inhibit major pathway splicing to
a lesser degree. Mutations which disrupt binding of both U1 and U11
abolished residual inhibitory activity often seen with the U1 binding
mutant, indicating that a low level inhibition could be due to U11.
Also, a moderate level of inhibition was observed when the U1 binding
mutants were inserted at a proximal intron position (24a).
Additionally, the authentic P120 minor 5' ss region inhibits splicing
of this construct to roughly the same degree as the mU1 mutant, but
again only when inserted at the intron proximal site (24a).
In these latter cases, it remains to be determined if the U11 site is
required or if the inhibition can be attributed to secondary U1 sites.
The very weak activity of U1 binding mutants when placed in the test
intron at a position similar to the native NRS location also calls into
question the significance of U11 binding for the virus. We are
currently incorporating specific U1 and U11 site mutations into the
virus in order to assess their effect on viral replication.
How might U1 snRNP bring about splicing inhibition when bound to the
NRS? Put another way, why, once it is bound, does splicing not occur
from the NRS to U2-dependent 3' ss? While these questions remain
unanswered, it does appear that the NRS U1 site must be in a suboptimal
form, since converting it to a consensus 5' ss activated splicing.
There is also no evidence for collaboration with U11, since in its
absence inhibition was efficient. We previously proposed that the NRS
might block splicing by the formation of a nonproductive complex
between factors bound to the NRS and the 3' ss and hypothesized that
U11 snRNP would be involved (23). The results of Cook and
McNally (8) indicate that an interaction does occur but that
it is not through U11, at least not in vitro. Rather, they showed that
U1 engages in an early interaction with factors associated with the
branch point/pyrimidine tract of an adenovirus U2-dependent 3' ss.
Inhibition might take place at this early stage directly through U1,
which could arrest spliceosome assembly. Alternatively, the observation
that an adenovirus splicing substrate harboring the NRS in the intron
failed to splice in vitro yet assembled abnormally large RNP complexes
with full spliceosomal snRNP representation argues that inhibition may
take place at subsequent spliceosome assembly steps, perhaps through
other snRNPs and/or non-snRNP factors. These issues are currently being
investigated in our laboratory.
 |
ACKNOWLEDGMENTS |
We thank Richard Padgett for P120 and U11 plasmids and Brent
Fogel for some of the NRS-P120 chimeric plasmids. We thank members of
the McNally lab for critical reviews of the manuscript.
This research was supported by a Public Health Service grant R29
CA63348 from the National Cancer Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Molecular Genetics, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226. Phone: (414) 456-8749. Fax:
(414) 456-6535. E-mail: mtm{at}mcw.edu.
 |
REFERENCES |
| 1.
|
Amendt, B. A.,
D. Hesslein,
L. J. Chang, and C. M. Stoltzfus.
1994.
Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1.
Mol. Cell. Biol.
14:3960-3970[Abstract/Free Full Text].
|
| 2.
|
Amendt, B. A.,
S. B. Simpson, and C. M. Stoltzfus.
1995.
Inhibition of RNA splicing at the Rous sarcoma virus src 3' splice site is mediated by an interaction between a negative cis element and a chicken embryo fibroblast nuclear factor.
J. Virol.
69:5068-5076[Abstract].
|
| 3.
|
Arrigo, S., and K. Beemon.
1988.
Regulation of Rous sarcoma virus RNA splicing and stability.
Mol. Cell. Biol.
8:4858-4867[Abstract/Free Full Text].
|
| 4.
|
Berberich, S. L., and C. M. Stoltzfus.
1991.
Mutations in the regions of the Rous sarcoma virus 3' splice sites: implications for regulation of alternative splicing.
J. Virol.
65:2640-2646[Abstract/Free Full Text].
|
| 5.
|
Bray, M.,
S. Prasad,
J. W. Dubay,
E. Hunter,
K. T. Jeang,
D. Rekosh, and M. L. Hammarskjold.
1994.
A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent.
Proc. Natl. Acad. Sci. USA
91:1256-1260[Abstract/Free Full Text].
|
| 6.
|
Coffin, J. M.
1996.
Retroviridae: the viruses and their replication, p. 1767-1847.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Raven Press, New York, N.Y.
|
| 7.
|
Cook, C. R., and M. T. McNally.
1996.
Characterization of an RNP complex that assembles on the Rous sarcoma virus negative regulator of splicing element.
Nucleic Acids Res.
24:4962-4968[Abstract/Free Full Text].
|
| 8.
|
Cook, C. R., and M. T. McNally.
1999.
Interaction between the negative regulator of splicing element and a 3' splice site: requirement for U1 small nuclear ribonucleoprotein and the 3' splice site branch point/pyrimidine tract.
J. Virol.
73:2394-2400[Abstract/Free Full Text].
|
| 9.
|
Cook, C. R., and M. T. McNally.
1998.
SR protein and snRNP requirements for assembly of the Rous sarcoma virus negative regulator of splicing complex in vitro.
Virology
242:211-220[Medline].
|
| 10.
|
Cullen, B. R.
1991.
Regulation of human immunodeficiency virus replication.
Annu. Rev. Microbiol.
45:219-250[Medline].
|
| 11.
|
Dietrich, R. C.,
R. Incorvaia, and R. A. Padgett.
1997.
Terminal intron dinucleotide sequences do not distinguish between U2- and U12-dependent introns.
Mol. Cell
1:151-160[Medline].
|
| 12.
|
Dignam, J. D.,
R. M. Lebovitz, and R. D. Roeder.
1983.
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acids Res.
11:1475-1489[Abstract/Free Full Text].
|
| 13.
|
Fu, X. D.
1995.
The superfamily of arginine/serine-rich splicing factors.
RNA
1:663-680[Medline].
|
| 14.
|
Gontarek, R. R.,
M. T. McNally, and K. Beemon.
1993.
Mutation of an RSV intronic element abolishes both U11/U12 snRNP binding and negative regulation of splicing.
Genes Dev.
7:1926-1936[Abstract/Free Full Text].
|
| 15.
|
Hall, S. L., and R. A. Padgett.
1994.
Conserved sequences in a class of rare eukaryotic nuclear introns with non-consensus splice sites.
J. Mol. Biol.
239:357-365[Medline].
|
| 16.
|
Hall, S. L., and R. A. Padgett.
1996.
Requirement of U12 snRNA for in vivo splicing of a minor class of eukaryotic nuclear pre-mRNA introns.
Science
271:1716-1718[Abstract].
|
| 17.
|
Katz, R. A.,
M. Kotler, and A. M. Skalka.
1988.
cis-acting intron mutations that affect the efficiency of avian retroviral RNA splicing: implication for mechanisms of control.
J. Virol.
62:2686-2695[Abstract/Free Full Text].
|
| 18.
|
Katz, R. A., and A. M. Skalka.
1990.
Control of retroviral RNA splicing through maintenance of suboptimal processing signals.
Mol. Cell. Biol.
10:696-704[Abstract/Free Full Text].
|
| 19.
|
Kohrman, D. C.,
J. B. Harris, and M. H. Meisler.
1996.
Mutation detection in the med and medJ alleles of the sodium channel Scn8a. Unusual splicing due to a minor class AT-AC intron.
J. Biol. Chem.
271:17576-17581[Abstract/Free Full Text].
|
| 20.
|
Kolossova, I., and R. A. Padgett.
1997.
U11 snRNA interacts in vivo with the 5' splice site of U12-dependent (AU-AC) pre-mRNA introns.
RNA
3:227-233[Abstract].
|
| 21.
|
Linial, M.
1987.
Creation of a processed pseudogene by retroviral infection.
Cell
49:93-102[Medline].
|
| 22.
|
Manley, J. L., and R. Tacke.
1996.
SR proteins and splicing control.
Genes Dev.
10:1569-1579[Free Full Text].
|
| 23.
|
McNally, L. M., and M. T. McNally.
1998.
An RNA splicing enhancer-like sequence is a component of a splicing inhibitor element from Rous sarcoma virus.
Mol. Cell. Biol.
18:3103-3111[Abstract/Free Full Text].
|
| 24.
|
McNally, L. M., and M. T. McNally.
1996.
SR protein splicing factors interact with the Rous sarcoma virus negative regulator of splicing element.
J. Virol.
70:1163-1172[Abstract].
|
| 24a.
| McNally, M. T. Unpublished data.
|
| 25.
|
McNally, M. T., and K. Beemon.
1992.
Intronic sequences and 3' splice sites control Rous sarcoma virus RNA splicing.
J. Virol.
66:6-11[Abstract/Free Full Text].
|
| 26.
|
McNally, M. T.,
R. R. Gontarek, and K. Beemon.
1991.
Characterization of Rous sarcoma virus intronic sequences that negatively regulate splicing.
Virology
185:99-108[Medline].
|
| 27.
|
Meric, C., and P. F. Spahr.
1986.
Rous sarcoma virus nucleic acid-binding protein p12 is necessary for viral 70S RNA dimer formation and packaging.
J. Virol.
60:450-459[Abstract/Free Full Text].
|
| 28.
|
Moore, M. J.,
C. C. Query, and P. A. Sharp.
1993.
Splicing of precursors to mRNA by the spliceosome, p. 303-357.
In
R. Gesteland, and J. Atkins (ed.), The RNA world. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 29.
|
Mount, S. M.
1996.
AT-AC introns; an ATtACk on dogma.
Science
271:1690-1691[Medline].
|
| 30.
|
Ogert, R. A.,
L. H. Lee, and K. L. Beemon.
1996.
Avian retroviral RNA element promotes unspliced RNA accumulation in the cytoplasm.
J. Virol.
70:3834-3843[Abstract].
|
| 31.
|
O'Reilly, M. M.,
M. T. McNally, and K. L. Beemon.
1995.
Two strong 5' splice sites and competing, suboptimal 3' splice sites involved in alternative splicing of human immunodeficiency virus type 1 RNA.
Virology
213:373-385[Medline].
|
| 32.
|
Purcell, D. F., and M. A. Martin.
1993.
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity.
J. Virol.
67:6365-6378[Abstract/Free Full Text].
|
| 33.
|
Saiki, R. K.,
D. H. Gelfand,
S. Stoffel,
S. Scharf,
R. H. Higuchi,
G. T. Horn,
K. B. Mulli, and H. A. Erlich.
1988.
Primer-directed enzymatic amplification with a thermostable DNA polymerase.
Science
239:487-491[Abstract/Free Full Text].
|
| 34.
|
Schwartz, D. E.,
R. Tizard, and W. Gilbert.
1983.
Nucleotide sequence of Rous sarcoma virus.
Cell
32:853-869[Medline].
|
| 35.
|
Schwartz, S.,
B. K. Felber,
D. M. Benko,
E.-M. Fenyo, and G. N. Pavlakis.
1990.
Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1.
J. Virol.
64:2519-2529[Abstract/Free Full Text].
|
| 36.
|
Si, Z. H.,
D. Rauch, and C. M. Stoltzfus.
1998.
The exon splicing silencer in human immunodeficiency virus type 1 Tat exon 3 is bipartite and acts early in spliceosome assembly.
Mol. Cell. Biol.
18:5404-5413[Abstract/Free Full Text].
|
| 37.
|
Simpson, S. B.,
L. Zhang,
R. C. Craven, and C. M. Stoltzfus.
1997.
Rous sarcoma virus direct repeat cis elements exert effects at several points in the virus life cycle.
J. Virol.
71:9150-9156[Abstract].
|
| 38.
|
Smith, C. W. J.,
J. G. Patton, and B. Nadal-Ginard.
1989.
Alternative splicing in the control of gene expression.
Annu. Rev. Genet.
23:527-577[Medline].
|
| 39.
|
Staffa, A., and A. Cochrane.
1995.
Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1.
Mol. Cell. Biol.
15:4597-4605[Abstract].
|
| 40.
|
Stoltzfus, C. M., and S. J. Fogarty.
1989.
Multiple regions in the Rous sarcoma virus src gene intron act in cis to affect the accumulation of unspliced RNA.
J. Virol.
63:1669-1676[Abstract/Free Full Text].
|
| 41.
|
Tarn, W. Y., and J. A. Steitz.
1996.
Highly diverged U4 and U6 small nuclear RNAs required for splicing rare AT-AC introns.
Science
273:1824-1832[Free Full Text].
|
| 42.
|
Tarn, W. Y., and J. A. Steitz.
1996.
A novel spliceosome containing U11, U12, and U5 snRNPs excises a minor class (AT-AC) intron in vitro.
Cell
84:801-811[Medline].
|
| 43.
|
Tarn, W. Y., and J. A. Steitz.
1997.
Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge.
Trends Biochem. Sci.
22:132-137[Medline].
|
| 44.
|
Valcarcel, J., and M. R. Green.
1996.
The SR protein family: pleiotropic functions in pre-mRNA splicing.
Trends Biochem. Sci.
21:296-301[Medline].
|
| 45.
|
Weldon, R. A., Jr., and J. W. Wills.
1993.
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release.
J. Virol.
67:5550-5561[Abstract/Free Full Text].
|
| 46.
|
Yu, Y. T., and J. A. Steitz.
1997.
Site-specific crosslinking of mammalian U11 and U6atac to the 5' splice site of an AT-AC intron.
Proc. Natl. Acad. Sci. USA
94:6030-6035[Abstract/Free Full Text].
|
| 47.
|
Zahler, A. M.,
K. M. Neugebauer,
J. A. Stolk, and M. B. Roth.
1993.
Human SR proteins and isolation of a cDNA encoding SRp75.
Mol. Cell. Biol.
13:4023-4028[Abstract/Free Full Text].
|
| 48.
|
Zhang, L.,
S. B. Simpson, and C. M. Stoltzfus.
1996.
Selection and characterization of replication-competent revertants of a Rous sarcoma virus src gene oversplicing mutant.
J. Virol.
70:3636-3644[Abstract].
|
| 49.
|
Zhang, L., and C. M. Stoltzfus.
1995.
A suboptimal src 3' splice site is necessary for efficient replication of Rous sarcoma virus.
Virology
206:1099-1107[Medline].
|
Journal of Virology, March 1999, p. 2385-2393, Vol. 73, No. 3
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Maciolek, N. L., McNally, M. T.
(2007). Serine/Arginine-Rich Proteins Contribute to Negative Regulator of Splicing Element-Stimulated Polyadenylation in Rous Sarcoma Virus. J. Virol.
81: 11208-11217
[Abstract]
[Full Text]
-
Akker, S. A., Misra, S., Aslam, S., Morgan, E. L., Smith, P. J., Khoo, B., Chew, S. L.
(2007). Pre-Spliceosomal Binding of U1 Small Nuclear Ribonucleoprotein (RNP) and Heterogenous Nuclear RNP E1 Is Associated with Suppression of a Growth Hormone Receptor Pseudoexon. Mol. Endocrinol.
21: 2529-2540
[Abstract]
[Full Text]
-
Buratti, E., Stuani, C., De Prato, G., Baralle, F. E.
(2007). SR protein-mediated inhibition of CFTR exon 9 inclusion: molecular characterization of the intronic splicing silencer. Nucleic Acids Res
35: 4359-4368
[Abstract]
[Full Text]
-
Qi, J., Su, S., Mattox, W.
(2007). The doublesex Splicing Enhancer Components Tra2 and Rbp1 Also Repress Splicing through an Intronic Silencer. Mol. Cell. Biol.
27: 699-708
[Abstract]
[Full Text]
-
Sauliere, J., Sureau, A., Expert-Bezancon, A., Marie, J.
(2006). The Polypyrimidine Tract Binding Protein (PTB) Represses Splicing of Exon 6B from the {beta}-Tropomyosin Pre-mRNA by Directly Interfering with the Binding of the U2AF65 Subunit. Mol. Cell. Biol.
26: 8755-8769
[Abstract]
[Full Text]
-
Wilusz, J. E., Beemon, K. L.
(2006). The Negative Regulator of Splicing Element of Rous Sarcoma Virus Promotes Polyadenylation. J. Virol.
80: 9634-9640
[Abstract]
[Full Text]
-
McNally, L. M., Yee, L., McNally, M. T.
(2006). Heterogeneous Nuclear Ribonucleoprotein H Is Required for Optimal U11 Small Nuclear Ribonucleoprotein Binding to a Retroviral RNA-processing Control Element: IMPLICATIONS FOR U12-DEPENDENT RNA SPLICING. J. Biol. Chem.
281: 2478-2488
[Abstract]
[Full Text]
-
Giles, K. E., Beemon, K. L.
(2005). Retroviral Splicing Suppressor Sequesters a 3' Splice Site in a 50S Aberrant Splicing Complex. Mol. Cell. Biol.
25: 4397-4405
[Abstract]
[Full Text]
-
McNally, L. M., Yee, L., McNally, M. T.
(2004). Two Regions Promote U11 Small Nuclear Ribonucleoprotein Particle Binding to a Retroviral Splicing Inhibitor Element (Negative Regulator of Splicing). J. Biol. Chem.
279: 38201-38208
[Abstract]
[Full Text]
-
CABELLO-VILLEGAS, J., GILES, K. E., SOTO, A. M., YU, P., MOUGIN, A., BEEMON, K. L., WANG, Y.-X.
(2004). Solution structure of the pseudo-5' splice site of a retroviral splicing suppressor. RNA
10: 1388-1398
[Abstract]
[Full Text]
-
GILES, K. E., CAPUTI, M., BEEMON, K. L.
(2004). Packaging and reverse transcription of snRNAs by retroviruses may generate pseudogenes. RNA
10: 299-307
[Abstract]
[Full Text]
-
Polony, T. S., Bowers, S. J., Neiman, P. E., Beemon, K. L.
(2003). Silent Point Mutation in an Avian Retrovirus RNA Processing Element Promotes c-myb-Associated Short-Latency Lymphomas. J. Virol.
77: 9378-9387
[Abstract]
[Full Text]
-
Zhu, H., Hasman, R. A., Young, K. M., Kedersha, N. L., Lou, H.
(2003). U1 snRNP-Dependent Function of TIAR in the Regulation of Alternative RNA Processing of the Human Calcitonin/CGRP Pre-mRNA. Mol. Cell. Biol.
23: 5959-5971
[Abstract]
[Full Text]
-
Fogel, B. L., McNally, L. M., McNally, M. T.
(2002). Efficient polyadenylation of Rous sarcoma virus RNA requires the negative regulator of splicing element. Nucleic Acids Res
30: 810-817
[Abstract]
[Full Text]
-
Paca, R. E., Hibbert, C. S., O'Sullivan, C. T., Beemon, K. L.
(2001). Retroviral Splicing Suppressor Requires Three Nonconsensus Uridines in a 5' Splice Site-Like Sequence. J. Virol.
75: 7763-7768
[Abstract]
[Full Text]
-
Côté, J., Dupuis, S., Jiang, Z.-H., Wu, J. Y.
(2001). Caspase-2 pre-mRNA alternative splicing: Identification of an intronic element containing a decoy 3' acceptor site. Proc. Natl. Acad. Sci. USA
10.1073/pnas.031564098v1
[Abstract]
[Full Text]
-
McCullough, A. J., Berget, S. M.
(2000). An Intronic Splicing Enhancer Binds U1 snRNPs To Enhance Splicing and Select 5' Splice Sites. Mol. Cell. Biol.
20: 9225-9235
[Abstract]
[Full Text]
-
Laverdiere, M., Beaudoin, J., Lavigueur, A.
(2000). Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene. Nucleic Acids Res
28: 1489-1497
[Abstract]
[Full Text]
-
Cook, C. R., McNally, M. T.
(1999). Interaction between the Negative Regulator of Splicing Element and a 3' Splice Site: Requirement for U1 Small Nuclear Ribonucleoprotein and the 3' Splice Site Branch Point/Pyrimidine Tract. J. Virol.
73: 2394-2400
[Abstract]
[Full Text]
-
Fogel, B. L., McNally, M. T.
(2000). A Cellular Protein, hnRNP H, Binds to the Negative Regulator of Splicing Element from Rous Sarcoma Virus. J. Biol. Chem.
275: 32371-32378
[Abstract]
[Full Text]
-
Cote, J., Dupuis, S., Wu, J. Y.
(2001). Polypyrimidine Track-binding Protein Binding Downstream of Caspase-2 Alternative Exon 9 Represses Its Inclusion. J. Biol. Chem.
276: 8535-8543
[Abstract]
[Full Text]
-
Pagani, F., Buratti, E., Stuani, C., Romano, M., Zuccato, E., Niksic, M., Giglio, L., Faraguna, D., Baralle, F. E.
(2000). Splicing Factors Induce Cystic Fibrosis Transmembrane Regulator Exon 9 Skipping through a Nonevolutionary Conserved Intronic Element. J. Biol. Chem.
275: 21041-21047
[Abstract]
[Full Text]
-
Cote, J., Dupuis, S., Jiang, Z.-H., Wu, J. Y.
(2001). Caspase-2 pre-mRNA alternative splicing: Identification of an intronic element containing a decoy 3' acceptor site. Proc. Natl. Acad. Sci. USA
98: 938-943
[Abstract]
[Full Text]